Survey on Alzheimer's Disease Prevalence Predicts Doubling in Patient Population in 20 Years

2006 ◽  
Vol 8 (3) ◽  
pp. 131
Author(s):  
&NA;
2016 ◽  
Vol 15 (S1) ◽  
Author(s):  
Dragan Gamberger ◽  
◽  
Bernard Ženko ◽  
Alexis Mitelpunkt ◽  
Nada Lavrač

2014 ◽  
Vol 10 ◽  
pp. S105-S110 ◽  
Author(s):  
Leslie Sibener ◽  
Ibrahim Zaganjor ◽  
Heather M. Snyder ◽  
Lisa J. Bain ◽  
Robert Egge ◽  
...  

1999 ◽  
Vol 10 (2) ◽  
pp. 97-100
Author(s):  
F Nourhashémi ◽  
S Andrieu ◽  
M.L Soléra ◽  
Y Rolland ◽  
P.J Ousset ◽  
...  

2006 ◽  
Vol 2 (1) ◽  
pp. 39-78
Author(s):  
Encarnita Raya-Ampil ◽  
Jeffrey L. Cummings

ABSTRACTDementia, particularly Alzheimer's disease (AD), is increasing by patient population included in clinical trials. The methodology for trials of AD patients have been defined in terms of outcomes, standard measures and analytic techniques. Trial methodology is evolving with experience as new potential therapies become available. Screening criteria, instrumentation choices, duration of trials and analytic strategies may have a profound impact on the conclusions that can be derived from trials. The components of AD trials are reviewed in detail in this chapter.


Sign in / Sign up

Export Citation Format

Share Document